Users Stopping Anti-Obesity Medications Put On Weight at a Quadrupled Rate Compared to Those on Conventional Diets

Fresh analysis suggests that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.

Published data in a major medical journal shows that while overweight people frequently drop about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.

"Users using such medications must be cognizant of the danger of fast rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.

Such speed of recovery suggests a reversion to starting weight in about a year and a half.

Weighing Approaches

The research, which examined 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.

Researchers note that people who lose weight through diet and exercise usually see a less rapid weight regain—around 100 grams monthly—after stopping.

Explaining the Quick Regain

Nutrition scientists suggest the mode of action of the injections is key to understanding the accelerated rebound.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Sustained high doses of the hormone levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making excessive eating a significant risk."

A Chronic Issue?

Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.

Professionals argue that, due to the likelihood of weight regain, the treatment is often ongoing.

This perspective is supported by drug manufacturers, who note that the results "emphasize the long-term nature of obesity," similar to managing diseases like diabetes.

User Experiences

Individuals who have stopped the medication explain a intense resurgence of appetite.

"It was like something activating and you become extremely hungry," described an individual.

This difficulty is exacerbated if users have not developed sustainable lifestyle or habit modifications during therapy.

Growing Use

Figures indicate that a significant number of people in the UK have used these injections in the past year, with demand remaining high.

• Adoption is higher among females than males.
• The 40s and 50s age group shows the highest usage rates.
• Many access the drugs through private prescriptions rather than public health services.

In conclusion, clinicians caution that while these medications are powerful tools for weight loss, they are not a magic fix and long-term success likely depends on combined lifestyle management.